Navigation Links
Chicken Anti-Human Complement Component C4c Antibody, Unconjugated from CEDARLANE Laboratories Limited

ProductsChicken Anti-Human Complement Component C4c Antibody, Unconjugated from CEDARLANE Laboratories Limited
Company CEDARLANE Laboratories Limited
Item Chicken Anti-Human Complement Component C4c Antibody, Unconjugated
Price $148.00
Description Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)
Info CEDARLANE Laboratories LimitedCEDARLANE Laboratories Limited
5516 - 8th Line, R.R.#2
Hornby, Ontario L0P 1E0
Canada
Customer Service:
(905) 878-8891
(800) 268-5058 Toll-Free North America

Fax Number:
(905) 878-7800

Web Site: http://www.cedarlanelabs.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Chicken Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
2. Chicken Anti-UCK2 Polyclonal Antibody, Unconjugated from Abcam
3. Chicken Anti-Corticoliberin Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
4. Chicken Anti-HADHSC Azide Free Polyclonal Antibody, Unconjugated from Abcam
5. Rabbit Anti-Chicken IgY, IgG F(ab)2 fragment Antibody, Rhodamine Conjugated from Biomeda Corporation
6. Rabbit Anti-Chicken IgY, IgG F(ab)2 fragment Antibody, Biotin Conjugated from Biomeda Corporation
7. Chicken Anti-Human Stomatin-like 2 (STOML2) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
8. Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
9. Chicken Anti-Polymerase (RNA) II (DNA directed) polypeptide L Antibody, Unconjugated from CHEMICON
10. Chicken Anti-Rab GDP dissociation inhibitor beta Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
11. Chicken Anti-HSPBP1 Polyclonal Antibody, Unconjugated from ProSci, Inc
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/22/2015)... 2015 According to a new ... 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware ... Consumer and Home) - Global Forecast to 2020", published ... Billion in 2015 to $6.19 Billion by 2020, at ... market data Tables and   43 Figures spread through ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... the Gulf of Mexico could soon catch the oil slick ... Keys, scientists are monitoring the situation closely with ESA,s Envisat ... information with Envisat Advanced Synthetic Aperture Radar (ASAR) data of ... direction in which the spill boundaries can drift. ,In these ...
... Arabinoxylan, the major dietary fibre component of wheat ... point of view. New enzymatic technologies were developed in ... The results offer potential for a new soluble fibre ... of cereal fibre, in particular in the prevention of ...
... A wide range of gluten free cereals have been ... of the European Union, and their impact on product ... as high-pressure processing technology have been successfully applied to ... free cereal products. In genetically susceptible individuals, the ...
Cached Biology News:Envisat monitors oil spill proximity to Loop Current 2New and improved gluten-free foods developed for patients with celiac disease 2
(Date:5/30/2015)... RARITAN, N.J. , May 30, 2015 ... single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment ... monoclonal antibody – achieved an overall response rate ... assessed by an independent review committee, in heavily ... consistent among the pre-specified subgroups based on age, ...
(Date:5/29/2015)... Los Gatos, CA (PRWEB) May 29, 2015 ... diagnostics company addressing multi-drug-resistant organisms (MDROs), announced that ... technology for same-shift bacterial detection and susceptibility testing ... asm2015 on May 31, 2015 in ... a new class of molecular diagnostics that can ...
(Date:5/29/2015)... Columbia, Pa. (PRWEB) May 29, 2015 ... Thermal Product Solutions with a request to design ... remove excess moisture from prescription medications being produced ... custom solution that includes a robotic gantry, heat-saving ... positions and dries trays of 3D-printed pills to ...
(Date:5/29/2015)... Results from a Phase III clinical trial examining ... reduce the size of melanoma tumors in patients injected ... of Clinical Oncology. , The global, randomized trial ... melanoma, a potentially fatal form of skin cancer. The ... safety and efficacy of the oncolytic virus immunotherapy compared ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2